Related Experiment Video

Updated: Oct 9, 2026

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

Perspectives of HER2-targeting in gastric and esophageal cancer

James N Gerson1, Sam Skariah2, Crystal S Denlinger1

  • 1a Department of Hemagology/Oncology , Fox Chase Cancer Center , Philadelphia , PA , USA.

Expert Opinion on Investigational Drugs
|April 8, 2017
PubMed
Abstract

Insights

Targeting human epidermal growth factor receptor 2 (HER2) improves outcomes for esophagogastric cancer. Ongoing research explores new anti-HER2 therapies and combinations, despite challenges from tumor heterogeneity and resistance.

Area of Science:

  • Oncology
  • Gastroenterology
  • Molecular Biology

Background:

  • Human epidermal growth factor receptor 2 (HER2) signaling blockade has improved outcomes for esophagogastric cancer patients.
  • Targeting HER2 remains challenging due to its complex biology in gastric and esophageal cancers.
  • Tumor heterogeneity in gastroesophageal cancer adds complexity to HER2-targeted therapies.

Purpose of the Study:

  • To review the complex biology of HER2 in gastroesophageal cancers.
  • To discuss current HER2 testing methodologies and tumor heterogeneity.
  • To analyze ongoing and completed clinical research on HER2-targeted treatments.

Main Methods:

  • Review of scientific literature on HER2 biology and gastroesophageal cancer.
  • Analysis of current HER2 testing techniques.
  • Discussion of clinical trial data for HER2-targeted therapies.

Main Results:

  • HER2 overexpression is a validated therapeutic target in gastroesophageal cancer.
  • HER2 inhibition in the first-line setting prolongs survival.
  • Standardized HER2 testing facilitates ongoing trials with novel agents and immunotherapy combinations.

Conclusions:

  • HER2 is a crucial target in gastroesophageal cancer, offering survival benefits.
  • Future research focuses on combining anti-HER2 antibodies with immunotherapy.
  • Addressing clonal heterogeneity and resistance is essential for improving treatment beyond frontline settings.
Keywords:
ErbB2HER2esophageal cancergastric cancertrastuzumab

More Related Videos

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT10:28

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Gastroesophageal Reflux Disease II: Clinical Features and Management01:29

Gastroesophageal Reflux Disease II: Clinical Features and Management

Gastroesophageal reflux disease, or GERD, is a persistent medical condition that affects many individuals worldwide. Its clinical manifestations can vary greatly, making diagnosis and management challenging for healthcare professionals. The following is a comprehensive overview of the clinical manifestations, assessment, and management strategies for GERD.
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
Barrett Esophagus-II: Clinical Manifestations and Management01:21

Barrett Esophagus-II: Clinical Manifestations and Management

Individuals with Barrett's esophagus are often asymptomatic, but they may experience symptoms commonly associated with GERD, such as heartburn and acid regurgitation. Additional symptoms can include difficulty swallowing, chest pain, unintentional weight loss, blood in the stool (which may appear black, tarry, or bloody), and episodes of vomiting.
To diagnose Barrett's esophagus, healthcare providers often recommend an endoscopy for those showing symptoms of acid reflux. The procedure entails...